Patents by Inventor Istvan Molnar

Istvan Molnar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230192364
    Abstract: In some examples, an instrument closure may include an instrument closure retainer to retain the instrument closure onto a container. The instrument closure may further include a sensor retainer including a plurality of apertures for transfer or removal of material, respectively, into or from the container. The sensor retainer may further include a sensor mount to retain a sensor.
    Type: Application
    Filed: November 30, 2022
    Publication date: June 22, 2023
    Applicant: AGILENT TECHNOLOGIES, INC.
    Inventors: Patrick MATZ, Matthias KAMUF, Manuel VAN VENROOY, István MOLNAR, Tobias ANHAUS
  • Publication number: 20220272975
    Abstract: The present invention relates to compositions and methods for preventing and/or treating plant parasitic nematodes. OIn particular, the present invention provides metabolites produced by Photorhabdus bacteria and use of such metabolites to treat or prevent nematode disease in plants.
    Type: Application
    Filed: July 9, 2020
    Publication date: September 1, 2022
    Inventors: Ayako Kusakabe, S. Patricia Stock, Istvan Molnar
  • Publication number: 20210259287
    Abstract: The present invention pertains to a device for controlling a gaseous mixture comprised in a portable enclosure as well as an enclosure comprising such device and a monitoring system comprising at least one corresponding enclosure. Accordingly, a device (1) for controlling a gaseous mixture (2) comprised in a portable enclosure (10) is suggested, which comprises a gas delivery device (3) for the delivery of at least one gaseous component (20, 22) to the gaseous mixture (2) and/or a gas removal device (4) for the removal of at least one gaseous component (20, 22) from the gaseous mixture (2), a gas monitor device (5) configured to detect at least one parameter (50) relating to the gaseous mixture (2), and a control unit (6) in communication with the gas monitor device (5) to receive the detected parameter and configured to determine an information (60) relating to the gaseous mixture (2) based on the received parameter (50).
    Type: Application
    Filed: June 7, 2019
    Publication date: August 26, 2021
    Inventors: Wolfgang SCHMEHL, Peter Geoffrey SENIOR, Kenth DROTT, Istvan MOLNAR, Markus WOLPERDINGER
  • Publication number: 20190328029
    Abstract: In order to overcome the limitations and problems that earlier apparatus and methods have experienced, a 3D printing head is disclosed having a nozzle, wherein the nozzle has: a material extrusion portion, and at least one protective gas injection portion co-acting with the material extraction portion. A related apparatus for 3D printing an article, in particular a food article, is also proposed. A related method of 3D printing an article, in particular a food article is also proposed.
    Type: Application
    Filed: December 18, 2017
    Publication date: October 31, 2019
    Applicant: Linde Aktiengesellschaft
    Inventor: Istvan Molnar
  • Patent number: 7654156
    Abstract: A distal tip of a fluid velocity probe generally includes at least a portion of a housing having first and second sidewalls defining a passageway therebetween, the passageway having inlet and outlet regions. The first and second sidewalls each are substantially symmetrical along an axis extending in the direction of the passageway through the center of each sidewall. The distal tip further includes a mass flow sensor disposed in the passageway between the inlet and outlet regions.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: February 2, 2010
    Assignee: Fluke Corporation
    Inventors: Brian Aikins, Zoltán István Molnár
  • Patent number: 7535235
    Abstract: An air flow sensor includes a sensor element and a microcontroller, employing a PWM signal to drive the sensor element. Signals from the sensor element are processed by the microcontroller inside the sensor, resulting in continuous readings of air velocity and air temperature.
    Type: Grant
    Filed: September 4, 2006
    Date of Patent: May 19, 2009
    Assignee: Fluke Corporation
    Inventor: Zoltan Istvan Molnar
  • Publication number: 20080121033
    Abstract: An air flow sensor includes a sensor element and a microcontroller, employing a PWM signal to drive the sensor element. Signals from the sensor element are processed by the microcontroller inside the sensor, resulting in continuous readings of air velocity and air temperature.
    Type: Application
    Filed: September 4, 2006
    Publication date: May 29, 2008
    Applicant: FLUKE CORPORATION
    Inventor: Zoltan Istvan Molnar
  • Patent number: 6858404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: February 22, 2005
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Publication number: 20030068788
    Abstract: Disclosed is a family of P450 monooxygenases, each member of which regioselectively oxidizes avermectin to 4″-keto-avermectin. The P450 monooxgenases find use in methods and formulations for making emamectin from avermectin. Also disclosed are methods for purifying the P450 monooxygenases of the invention, binding agents that specifically bind to the P450 monooxygenases of the invention, and genetically engineered cells that express the P450 monooxygenases of the invention. Also disclosed are ferredoxins and ferredoxin reductases that are active with the P450 monooxygenases of the invention.
    Type: Application
    Filed: May 14, 2002
    Publication date: April 10, 2003
    Inventors: Thomas Gunther Buckel, Philip Eugene Hammer, Dwight Steven Hill, James Madison Ligon, Istvan Molnar Durham, Johannes Paul Pachlatko, Ross Eric Zirkle
  • Publication number: 20020192778
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Application
    Filed: November 13, 2001
    Publication date: December 19, 2002
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jorn Gorlach
  • Patent number: 6383787
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: May 7, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6358719
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355459
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355458
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355457
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6346404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6121029
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: September 19, 2000
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jorn Gorlach
  • Patent number: 4526898
    Abstract: 4-(2-Imidazolin-2-yl-amino)-2-methyl-indazole is a highly selective and effective .alpha..sub.2 -antagonist, .alpha..sub.1 -partial agonist and .alpha..sub.1s -agonist and displays anti-hypertensive activity and antagonistic activity on adrenaline and noradrenaline. It is useful as an .alpha.-adrenoceptor influencing and as an anti-hypertensively active drug.
    Type: Grant
    Filed: September 7, 1983
    Date of Patent: July 2, 1985
    Assignee: Siegfried Aktiengesselschaft
    Inventors: Istvan Molnar, Kurt Thiele, Felix Geissmann, Ulrich Jahn
  • Patent number: 4436913
    Abstract: 1H- and 2H- indazole derivatives and pharmaceuticals containing these blood-pressure lowering 1H- and 2H- indazole derivatives of the formula ##STR1## and their acid addition salts, wherein R1 may be in position 1 or position 2 on the nitrogen atoms in formula I. The groups R1, R2 and R3 represent hydrogen or the usual lower molecular groups. The R group is a 2-imidazolinylamino group or a 3,4,5,6-tetryhydropyrimidinylamino group, wherein these groups may also be present in their tautomeric forms. These groups may also be in an aryl group in the R1 group, in which case the R group may also be a halogen atom. R may only represent one of the heterocyclic secondary or tertiary amino groups in the 4 or 7 position for the 1H- indazole derivatives when the R1 group is simultaneously an aryl or an aralkyl group.
    Type: Grant
    Filed: April 28, 1982
    Date of Patent: March 13, 1984
    Assignee: Siegfried Aktiengesellschaft
    Inventors: Istvan Molnar, Kurt Thiele, Felix Geissmann, Ulrich Jahn